Flyer

Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

James A Charles

Holy Name Medical Center, Montclair University, New Jersey, USA

Publications
  • Research Article   
    Recurrence of acute migraine following ubrogepant and diclofenac buffered solution combination therapy- An observational study
    Author(s): James A Charles* and Nicole Suttora

    Objective: To analyze the need for a repeat dose following administration of a single fixed combination dose of ubrogepant and diclofenac potassium buffered solution for an acute migraine attack. Background: A relapse after pain freedom/relief from a migraine abortive is an acute treatment failure. Reduction of acute disability and prevention of chronification is dependent on effective, rapid, complete abortive treatment without adverse effects. Methods: Ubrogepant 100 mg tabs and diclofenac potassium buffered solution 50 mg powder (UBR/DICb) are both FDA approved for acute migraine therapy. Twenty-three subjects, 22 female, 1 male with episodic or chronic migraine with and without aura were instructed take both agents within 15 minutes of the migraine attack. Pain freedom and pa.. View More»

    Abstract HTML PDF